Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and PharmaEngine Inc. have entered into a distribution agreement concerning Liporaxel (paclitaxel oral solution). The agreement grants PharmaEngine exclusive rights to handle the new drug application (NDA) filing, sales, and marketing of Liporaxel in the Taiwan market. Financial details of the deal remain undisclosed.
Liporaxel’s Development and Market Expansion
Liporaxel, developed and manufactured by Daehwa Pharmaceutical Co., Ltd., was licensed to RMX Bio for development, manufacturing, and commercialization in Mainland China, Taiwan, Hong Kong, and Thailand in September 2017. The drug initially received marketing approval in South Korea in September 2016 for the treatment of patients with advanced, metastatic, and recurrent gastric cancers. It recently gained marketing approval in China in September 2024 for use in patients with advanced gastric cancers. Liporaxel stands as the first oral paclitaxel product to be successfully developed and approved globally.- Flcube.com
